Botulinum neurotoxins in the treatment of refractory pain
- 1 December 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Neurology
- Vol. 4 (12), 676-685
- https://doi.org/10.1038/ncpneuro0948
Abstract
The proper management of pain is a critical issue in the practice of medicine. Despite the availability of a large number of analgesic medications, management of pain that is refractory to conventional treatments remains a challenge for both clinicians and surgeons. Botulinum neurotoxin (BoNT) has recently emerged as a potential novel approach to control pain. Animal studies have revealed a number of mechanisms by which BoNTs can influence and alleviate chronic pain, including inhibition of pain peptide release from nerve terminals and sensory ganglia, anti-inflammatory and antiglutaminergic effects, reduction of sympathetic neural discharge, and inhibition of muscle spindle discharge. In humans, prospective, placebo-controlled, double-blind studies have also provided evidence for effectiveness of BoNT therapy in a number of painful disorders. These include cervical dystonia, pelvic pain, low back pain, plantar fasciitis, postsurgical painful spasms, myofascial pain syndromes, migraine, and chronic daily headaches. Long-term studies on cervical dystonia and low back pain have demonstrated safety and sustained efficacy after repeated injections. This Review focuses on the analgesic effects of BoNT and the mechanisms of its pain control as revealed by animal models, and provides evidence-based data on the efficacy of BoNT therapy in various pain syndromes in humans.Keywords
This publication has 64 references indexed in Scilit:
- Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammationBJU International, 2008
- The treatment of cervical dystonia with botulinum toxinsJournal of Neural Transmission, 2007
- A Double-Blind, Randomized, Placebo-Controlled Comparison of Botulinum Toxin Type A Injection Sites and Doses in the Prevention of Episodic MigrainePain Medicine, 2007
- Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Tension-Type Headache: A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group StudyCephalalgia, 2006
- Treatment of Refractory, Chronic Low Back Pain with Botulinum Neurotoxin A: An Open-Label, Pilot StudyPain Medicine, 2006
- Treatment of Pain Attributed to Plantar Fasciitis with Botulinum Toxin AAmerican Journal of Physical Medicine & Rehabilitation, 2005
- Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- Effect of Botulinum Toxin A Injections in the Treatment of Chronic Tension‐type Headache: A Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2001